Two clinical trials (phase I and phase II) are currently testing the combination of ipilimumab (anti-CTLA-4) and bevacizumab in melanoma patients (stage III-IV), focusing on the effect on OS and PFS (NCT01950390) (ClinicalTrials.gov, started in 2013, accessed on 25 March 2021) [159] and on the maximum dose tolerated (NCT00790010) (ClinicalTrials.gov, started in 2008, accessed on 25 March 2021) [160]. Here, CTLA4 is linked to melanoma.